Table 3.

Time trends in prevalence of medical comorbidity (in %) from 1993 to 2005 in patients undergoing primary THA

	1993-1995	1996-1998	1999-2001	2002-2005	P-value
Deyo-Charlson comorbidities
Myocardial Infarction	4.0	4.2	4.1	4.7	0.76
Congestive Heart Failure	2.5	2.8	3.5	4.1	0.05
Peripheral Vascular Disease	4.7	3.8	4.2	5.6	0.07
Cerebrovascular disease	5.5	5.2	6.3	7.9	0.006
Dementia	0	0	0.3	0.4	0.02
COPD	9.7	8.8	10.2	9.7	0.66
Peptic ulcer disease	5.5	6.3	6.2	6.3	0.81
Mild liver disease	1.4	0.6	1.1	1.2	0.20
Diabetes	4.8	5.0	5.9	8.0	<0.001
Diabetes with end organ damage	0.9	0.7	1.8	2.0	0.005
Hemiplegia	0.3	0.2	0.2	0.5	0.48
Moderate/severe renal disease	2.6	3.2	5.4	5.9	<0.001
Moderate/severe liver disease	0.5	0.3	0.2	0.3	0.58
Metastatic solid tumor	3.3	2.3	3.6	2.7	0.12
AIDS	0	0.1	0	0	0.32
Rheumatologic disease	6.1	5.2	5.4	5.2	0.67
Other cancer	11.2	10.9	13.5	13.9	0.02
Mean Deyo-Charlson score (SD)	0.9 (1.8)	0.9 (1.7)	1.1 (2.0)	1.1 (2.0)	<0.001

COPD, Chronic Obstructive Pulmonary Disease; AIDS, Acquired Immune Deficiency Disease; SD, standard deviation.

Significant p-values are in bold, calculated with chi-squared test.